The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Celmatix's Fertilome test aims to give women genetic insight into their fertility.
Trial studying the use of next-generation sequencing-based pre-implantation genetic screening has its first birth, the Guardian reports.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.
They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.